Over the past six months, numerous pharmaceutical companies have announced plans to invest in new U.S. manufacturing facilities within the next decade. This so-called “onshoring,” motivated by the Trump administration’s announcement of sector-specific tariffs, seems to make sense on the surface: strengthen domestic manufacturing capabilities and mitigate potential risks of supply disruption. Given the years of time it takes to build a new manufacturing facility, the president signed a separate order to hasten the FDA approval process for domestic drug manufacturing plants, while simultaneously increasing fees and inspections for foreign facilities.

These initiatives have a clear goal, to “put America first.” But that political imperative may be achieved more efficiently and quickly

See Full Page